Australia's most trusted
source of pharma news
Posted 11 October 2024 AM
An Eli Lilly funded report exposing the hidden cost of Alzheimer's disease (AD) has been unveiled in Parliament House Canberra as the company looks to bring its treatment Kisunla to market.
The 'Diagnosis to Dignity - A Vision for Alzheimer's Disease in Australia' report conducted by Evohealth in collaboration with medical experts and advocates, warns that the economic cost of the disease is expected to grow from $8.1 billion in 2024 to $17 billion in 2050, if urgent change is not prioritised.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.